Receipt of long-acting injectable antiretroviral therapy among people with HIV in Southern US states: an assessment using electronic health records and claims data
Abstract Background In January 2021, the United States (US) Food and Drug Administration (FDA) approved the first long-acting injectable antiretroviral therapy (LAI ART) regimen for the treatment of HIV providing an alternative to daily oral regimens. We analyzed electronic health records (EHRs) to...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-02-01
|
| Series: | AIDS Research and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12981-024-00690-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832571303071055872 |
|---|---|
| author | Yiyang Liu Rebecca J. Fisk-Hoffman Maitri Patel Robert L. Cook Mattia Prosperi |
| author_facet | Yiyang Liu Rebecca J. Fisk-Hoffman Maitri Patel Robert L. Cook Mattia Prosperi |
| author_sort | Yiyang Liu |
| collection | DOAJ |
| description | Abstract Background In January 2021, the United States (US) Food and Drug Administration (FDA) approved the first long-acting injectable antiretroviral therapy (LAI ART) regimen for the treatment of HIV providing an alternative to daily oral regimens. We analyzed electronic health records (EHRs) to provide real-world evidence of demographic and clinical characteristics associated with the receipt of LAI ART among people with HIV (PWH). Methods Leveraging EHRs from a large clinical research network in the Southern US - OneFlorida + linked with Medicaid (updated to 08/2022) - we identified a cohort of PWH who have been prescribed at least one dose of LAI ART since January 2021 and characterized their demographics, clinical characteristics, and HIV care outcomes. Results A total of 233 LAI ART recipients were identified: 56.7% female, 45.1% aged 30 to 44, 51.3% non-Hispanic Black, 78.1% on Medicaid and 4.7% on private insurance. Approximately three-quarters of injections (71.2%) were received within 37 days of the previous dose, and 84.4% were received within 67 days. About 8% of LAI ART recipients did not have optimal care engagement the year before LAI ART initiation; one in five recipients had a diagnosis of alcohol or substance use disorder in lifetime. All achieved viral suppression (< 50 copies/mL) before starting LAI ART. Of a subset of patients with HIV viral load test records, only 1 record of virologic failure (viral load > 200 copies/ml) was observed after the initiation of LAI ART. Discussion There has been an increasing trend of LAI ART initiation since approval. People with suboptimal care engagement and with substance use disorder in lifetime were not excluded from LAI ART treatment. |
| format | Article |
| id | doaj-art-5b2e40e5c7fb4733b482f48d68a9d939 |
| institution | Kabale University |
| issn | 1742-6405 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | BMC |
| record_format | Article |
| series | AIDS Research and Therapy |
| spelling | doaj-art-5b2e40e5c7fb4733b482f48d68a9d9392025-02-02T12:43:21ZengBMCAIDS Research and Therapy1742-64052025-02-012211910.1186/s12981-024-00690-9Receipt of long-acting injectable antiretroviral therapy among people with HIV in Southern US states: an assessment using electronic health records and claims dataYiyang Liu0Rebecca J. Fisk-Hoffman1Maitri Patel2Robert L. Cook3Mattia Prosperi4Department of Epidemiology, College of Public Health and Health Professions and College of Medicine, University of FloridaDepartment of Epidemiology, College of Public Health and Health Professions and College of Medicine, University of FloridaDepartment of Epidemiology, College of Public Health and Health Professions and College of Medicine, University of FloridaDepartment of Epidemiology, College of Public Health and Health Professions and College of Medicine, University of FloridaDepartment of Epidemiology, College of Public Health and Health Professions and College of Medicine, University of FloridaAbstract Background In January 2021, the United States (US) Food and Drug Administration (FDA) approved the first long-acting injectable antiretroviral therapy (LAI ART) regimen for the treatment of HIV providing an alternative to daily oral regimens. We analyzed electronic health records (EHRs) to provide real-world evidence of demographic and clinical characteristics associated with the receipt of LAI ART among people with HIV (PWH). Methods Leveraging EHRs from a large clinical research network in the Southern US - OneFlorida + linked with Medicaid (updated to 08/2022) - we identified a cohort of PWH who have been prescribed at least one dose of LAI ART since January 2021 and characterized their demographics, clinical characteristics, and HIV care outcomes. Results A total of 233 LAI ART recipients were identified: 56.7% female, 45.1% aged 30 to 44, 51.3% non-Hispanic Black, 78.1% on Medicaid and 4.7% on private insurance. Approximately three-quarters of injections (71.2%) were received within 37 days of the previous dose, and 84.4% were received within 67 days. About 8% of LAI ART recipients did not have optimal care engagement the year before LAI ART initiation; one in five recipients had a diagnosis of alcohol or substance use disorder in lifetime. All achieved viral suppression (< 50 copies/mL) before starting LAI ART. Of a subset of patients with HIV viral load test records, only 1 record of virologic failure (viral load > 200 copies/ml) was observed after the initiation of LAI ART. Discussion There has been an increasing trend of LAI ART initiation since approval. People with suboptimal care engagement and with substance use disorder in lifetime were not excluded from LAI ART treatment.https://doi.org/10.1186/s12981-024-00690-9HIVLong-acting antiretroviral therapyElectronic health recordsCabotegravir/Rilpivirine |
| spellingShingle | Yiyang Liu Rebecca J. Fisk-Hoffman Maitri Patel Robert L. Cook Mattia Prosperi Receipt of long-acting injectable antiretroviral therapy among people with HIV in Southern US states: an assessment using electronic health records and claims data AIDS Research and Therapy HIV Long-acting antiretroviral therapy Electronic health records Cabotegravir/Rilpivirine |
| title | Receipt of long-acting injectable antiretroviral therapy among people with HIV in Southern US states: an assessment using electronic health records and claims data |
| title_full | Receipt of long-acting injectable antiretroviral therapy among people with HIV in Southern US states: an assessment using electronic health records and claims data |
| title_fullStr | Receipt of long-acting injectable antiretroviral therapy among people with HIV in Southern US states: an assessment using electronic health records and claims data |
| title_full_unstemmed | Receipt of long-acting injectable antiretroviral therapy among people with HIV in Southern US states: an assessment using electronic health records and claims data |
| title_short | Receipt of long-acting injectable antiretroviral therapy among people with HIV in Southern US states: an assessment using electronic health records and claims data |
| title_sort | receipt of long acting injectable antiretroviral therapy among people with hiv in southern us states an assessment using electronic health records and claims data |
| topic | HIV Long-acting antiretroviral therapy Electronic health records Cabotegravir/Rilpivirine |
| url | https://doi.org/10.1186/s12981-024-00690-9 |
| work_keys_str_mv | AT yiyangliu receiptoflongactinginjectableantiretroviraltherapyamongpeoplewithhivinsouthernusstatesanassessmentusingelectronichealthrecordsandclaimsdata AT rebeccajfiskhoffman receiptoflongactinginjectableantiretroviraltherapyamongpeoplewithhivinsouthernusstatesanassessmentusingelectronichealthrecordsandclaimsdata AT maitripatel receiptoflongactinginjectableantiretroviraltherapyamongpeoplewithhivinsouthernusstatesanassessmentusingelectronichealthrecordsandclaimsdata AT robertlcook receiptoflongactinginjectableantiretroviraltherapyamongpeoplewithhivinsouthernusstatesanassessmentusingelectronichealthrecordsandclaimsdata AT mattiaprosperi receiptoflongactinginjectableantiretroviraltherapyamongpeoplewithhivinsouthernusstatesanassessmentusingelectronichealthrecordsandclaimsdata |